Embelin and TRAIL Receptor 2 mAb-induced Apoptosis of TRAIL-resistant A549 Non-small Cell Lung Cancer Cells
نویسندگان
چکیده
Lung cancer is a highly malignant disease with an extremely poor prognosis (Field and Duffy, 2008), and 80%-85% of the total lung cancer cases are attributed to non-small cell lung cancer (NSCLC). Platinum-based chemotherapy has long been the standard treatment for advanced NSCLC (De Petris et al., 2006). However, NSCLC displays intrinsic or acquired resistance towards many conventional chemotherapeutic agents, and the median survival time for NSCLC remains poor (Ihde and Minna 1991; Stegehuis et al., 2009). Thus novel treatment strategies are badly needed to improve the outcomes of patients with this disease. A promising candidate for cancer therapeutics might be the tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL). Different studies have shown that TRAIL is capable of inducing apoptosis in a considerable number of cancer cells, while showing no significant adverse effects on normal cells and tissues (Mahalingam et al., 2009). TRAIL induces apoptosis upon binding to its death domain-containing receptors, TRAIL receptor 1
منابع مشابه
Synergistic Effect of Subtoxic-dose Cisplatin and TRAIL to Mediate Apoptosis by Down-regulating Decoy Receptor 2 and Up-regulating Caspase-8, Caspase-9 and Bax Expression on NCI-H460 and A549 Cells
Objective(s): Although tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can selectively induce apoptosis in tumor cells, more than half of tumors including non-small cell lung cancer (NSCLC) exhibit TRAIL-resistance. The purpose of this study was to determine whether subtoxic-dose cisplatin and TRAIL could synergistically enhance apoptosis on NSCLC cells and investigate its under...
متن کاملTargeting lung cancer stem-like cells with TRAIL gene armed oncolytic adenovirus
Lung cancer stem cell (LCSC) is critical in cancer initiation, progression, drug resistance and relapse. Disadvantages showed in conventional lung cancer therapy probably because of its existence. In this study, lung cancer cell line A549 cells propagated as spheroid bodies (named as A549 sphere cells) in growth factors-defined serum-free medium. A549 sphere cells displayed CSC properties, incl...
متن کاملDecoy receptor-2 small interfering RNA (siRNA) strategy employing three different siRNA constructs in combination defeats adenovirus-transferred tumor necrosis factor-related apoptosis-inducing ligand resistance in lung cancer cells.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) selectively induces apoptosis in cancer cells but not in normal cells. However, studies have indicated that more than half of human tumors exhibit TRAIL resistance. Although the mechanism of TRAIL resistance is not understood, it represents a barrier to any TRAIL-mediated gene therapy approach. In addition, no correlation bet...
متن کاملKinome profiling of non-canonical TRAIL signaling reveals RIP1-Src-STAT3-dependent invasion in resistant non-small cell lung cancer cells.
Tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) triggers apoptosis selectively in tumor cells through interaction with TRAIL-R1/DR4 or TRAIL-R2/DR5 and this process is considered a promising avenue for cancer treatment. TRAIL resistance, however, is frequently encountered and hampers anti-cancer activity. Here we show that whereas H460 non-small cell lung cancer (NSCLC) ce...
متن کاملApigenin potentiates TRAIL therapy of non-small cell lung cancer via upregulating DR4/DR5 expression in a p53-dependent manner
Apigenin (APG) is an edible plant-derived flavonoid that shows modest antitumor activities in vitro and in vivo. APG treatment results in cell growth arrest and apoptosis in various types of tumors by modulating several signaling pathways. In the present study, we evaluated interactions between APG and TRAIL in non-small cell lung cancer (NSCLC) cells. We observed a synergistic effect between A...
متن کامل